State Street Corp Purchases 3,863 Shares of Penumbra, Inc. (NYSE:PEN)

State Street Corp boosted its stake in Penumbra, Inc. (NYSE:PEN - Free Report) by 0.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,236,671 shares of the company's stock after buying an additional 3,863 shares during the quarter. State Street Corp owned approximately 3.22% of Penumbra worth $240,298,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of PEN. Renaissance Technologies LLC purchased a new stake in shares of Penumbra in the second quarter valued at about $17,943,000. Thrivent Financial for Lutherans increased its holdings in Penumbra by 3,832.3% during the third quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company's stock worth $71,564,000 after buying an additional 358,932 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in Penumbra in the third quarter worth about $1,092,000. AlphaCentric Advisors LLC purchased a new position in Penumbra in the third quarter valued at about $777,000. Finally, LMR Partners LLP bought a new position in shares of Penumbra during the 3rd quarter valued at approximately $2,330,000. 88.88% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Penumbra

In other Penumbra news, CAO Lambert Shiu sold 1,798 shares of Penumbra stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $242.56, for a total value of $436,122.88. Following the transaction, the chief accounting officer now directly owns 20,682 shares of the company's stock, valued at $5,016,625.92. The trade was a 8.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $190.76, for a total transaction of $114,456.00. Following the sale, the executive vice president now directly owns 60,488 shares of the company's stock, valued at $11,538,690.88. The trade was a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,418 shares of company stock worth $10,624,973 over the last 90 days. Corporate insiders own 5.00% of the company's stock.

Penumbra Price Performance

NYSE PEN traded down $1.12 on Thursday, hitting $252.54. The stock had a trading volume of 409,422 shares, compared to its average volume of 376,213. The firm has a 50-day moving average of $225.17 and a 200-day moving average of $201.01. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 5.82. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $277.34. The company has a market capitalization of $9.69 billion, a price-to-earnings ratio of 292.59, a price-to-earnings-growth ratio of 2.39 and a beta of 0.51.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.69 by $0.16. The company had revenue of $301.04 million during the quarter, compared to analyst estimates of $297.36 million. Penumbra had a return on equity of 8.99% and a net margin of 2.97%. Penumbra's revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Equities analysts expect that Penumbra, Inc. will post 2.81 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PEN shares. Royal Bank of Canada lifted their price target on shares of Penumbra from $205.00 to $222.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th. Citigroup upped their price target on Penumbra from $220.00 to $245.00 and gave the company a "neutral" rating in a research report on Wednesday. BTIG Research lifted their price objective on Penumbra from $232.00 to $270.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Canaccord Genuity Group boosted their price objective on Penumbra from $260.00 to $323.00 and gave the company a "buy" rating in a research note on Monday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research note on Thursday, October 31st. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $252.42.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.